118 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
of linvoseltamab, a bispecific antibody targeting BCMA and CD3, in patients with relapsed/refractory multiple myeloma at the 65th American Society … 31, 2024, and a regulatory application is also under review in the EU.
The Company presented, at European Society for Medical Oncology Immuno-Oncology
8-K
EX-99.1
6bsbw g3xdprrfaj
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T
EX-99
iny8d7h1xrq1d 0cw
25 Aug 23
Third party tender offer statement
7:46am
8-K
EX-99.1
3iva5e3dyyynv nr8
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
PX14A6G
0kin1 6bbi
18 May 23
Letter to shareholders
4:46pm
8-K
EX-99.1
krfjb5r
3 Nov 22
Regeneron Reports Third Quarter 2022 Financial and Operating Results
7:19am
SC TO-T
EX-99
4hb6 ttkkz
2 May 22
Third party tender offer statement
7:48am
DEFA14A
tv03rmkb
21 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
EX-10.1
trabivyeq4oo vpb8gy
8 Mar 22
Entry into a Material Definitive Agreement
6:15am
8-K
EX-99.1
i8x5kh5w nzh2zwy
4 Feb 22
Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
7:29am